

IN THE SPECIFICATION

Please replace the paragraph beginning at page 1, line 11, with the following rewritten paragraph:

However, it is suggested that abnormal activation of these immunocompetent cells may cause various diseases, for example, hepatopathy (Kaneko Y., et al., *J. Exp. Med.*, 2000, Jan. 3; 191(1): 105-14, Nakamura K., et al., *J. Hepatol.*, 2001, Aug.; 35(2): 217-24, Tiegs G., et al., *J. Clin. Invest.*, 1992 Jul.; 90(1): 196-203), asthma (Akbari O., et al., *Nat. Med.*, 2003, May; 9(5): 582-8, Linden A., *Int. Arch. Allergy Immunol.*, 2001, Nov.; 126(3): 179-84, Corrigan CJ., *Chem. Immunol.*, 2000; 78: 39-49), arthritis (Chiba A Sköld M., et al., *Infect. Immun.*, 2003, Oct.; 71(10): 5447-55, Nurieva RI., *J. Clin. Invest.*, 2003, Mar.; 111(5): 701-6, Taylor PC., *Curr. Opin. Pharmacol.*, 2003, Jun.; 3(3): 323-8), diabetes (Hong S., et al., *Nat. Med.*, 2001, Sep.; 7(9): 1052-6, Hahn HJ., *Diabetes Metab. Rev.*, 1993, Dec.; 9(4): 323-8), lupus (Zeng D., *J. Clin. Invest.*, 2003, Oct.; 112(8): 1211-22, Olive D., et al., *Crit. Rev. Ther. Drug Carrier Syst.*, 1993; 10(1): 29-63), multiple sclerosis (Singh AK., *J. Exp. Med.*, 2001, Dec. 17; 194(12): 1801-11, Maatta JA., et al., *J. Neuroimmunol.*, 1998, Oct. 1; 90(2): 162-75, Milici AJ., et al., *Lab. Invest.*, 1998, Oct.; 78(10): 1239-44), arteriosclerosis (Tupin E. et al., *J. Exp. Med.*, 2004, Feb. 2; 199(3): 417-22), lung fibrosis (Keane MP., et al., *J. Immunol.*, 1999, May 1; 162(9): 5511-8, Hu H., et al., *J. Leukoc. Biol.*, 1993, Nov.; 54(5): 414-22).

Please replace the paragraph beginning at page 12, line 13, with the following rewritten paragraph:

The OPN-related peptide and the biopolymer compound are bound together by known methods, for example the mix acid anhydride process (B.F. Erlanger et al., (1954 1959): *J.*

*Biol. Chem.*, 234, 1090-1094) or the activated ester process (A.E. Karu et al., (1994): *J. Agric. Food Chem.*, 42, 301-309).

Please replace the paragraph beginning at page 16, line 24, with the following rewritten paragraph:

Further, according to a general method, the above-mentioned OPN-inhibitory antibody can be modified into a chimera antibody so that the antibody could have the same constant region as that of the antibody of a human that is a subject for therapy (see European Patent Publication EP0125023) or into a humanized antibody (see European Patent Publication EP0239400 or ~~EP0455126~~ 0451216, International Publication WO03/027151).